NASDAQ:APTO Aptose Biosciences - APTO Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Aptose Biosciences Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $0.59 +0.05 (+9.32%) (As of 03/20/2023 12:00 AM ET) Add Compare Share Share Today's Range$0.52▼$0.6050-Day Range$0.53▼$0.7652-Week Range$0.43▼$1.55Volume360,385 shsAverage Volume108,269 shsMarket Capitalization$54.19 millionP/E RatioN/ADividend YieldN/APrice Target$5.50 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Aptose Biosciences MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside837.4% Upside$5.50 Price TargetShort InterestHealthy0.21% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.38Based on 3 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($0.46) to ($0.47) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.06 out of 5 starsMedical Sector495th out of 988 stocksBiological Products, Except Diagnostic Industry85th out of 162 stocks 3.5 Analyst's Opinion Consensus RatingAptose Biosciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $5.50, Aptose Biosciences has a forecasted upside of 837.4% from its current price of $0.59.Amount of Analyst CoverageAptose Biosciences has received no research coverage in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted0.21% of the float of Aptose Biosciences has been sold short.Short Interest Ratio / Days to CoverAptose Biosciences has a short interest ratio ("days to cover") of 0.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Aptose Biosciences has recently increased by 0.69%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldAptose Biosciences does not currently pay a dividend.Dividend GrowthAptose Biosciences does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for APTO. Previous Next 3.0 News and Social Media Coverage News SentimentAptose Biosciences has a news sentiment score of 0.38. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Aptose Biosciences this week, compared to 1 article on an average week.Search Interest8 people have searched for APTO on MarketBeat in the last 30 days. This is an increase of 60% compared to the previous 30 days.MarketBeat Follows2 people have added Aptose Biosciences to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Aptose Biosciences insiders have not sold or bought any company stock.Percentage Held by Insiders10.94% of the stock of Aptose Biosciences is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 26.60% of the stock of Aptose Biosciences is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Aptose Biosciences are expected to decrease in the coming year, from ($0.46) to ($0.47) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Aptose Biosciences is -0.96, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Aptose Biosciences is -0.96, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAptose Biosciences has a P/B Ratio of 0.72. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Aptose Biosciences (NASDAQ:APTO) StockAptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies. The company has an agreement with CrystalGenomics, Inc. to research, develop, and commercialize CG026806, a non-covalent small molecule therapeutic agent, which is in preclinical stage for the treatment of acute myeloid leukemia and chronic lymphocytic leukemia/mantle cell lymphoma. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was founded in 1986 and is headquartered in Mississauga, Canada.Read More Receive APTO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Aptose Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address APTO Stock News HeadlinesMarch 21, 2023 | americanbankingnews.comAptose Biosciences (APTO) Scheduled to Post Quarterly Earnings on ThursdayMarch 19, 2023 | americanbankingnews.comAptose Biosciences (NASDAQ:APTO) Earns Hold Rating from Analysts at StockNews.comMarch 21, 2023 | Behind the Markets (Ad)Buy THIS stock before Taiwan is attacked... If the United States goes to war with another nuclear armed superpower, this could have a devastating impact on your retirement portfolio. Now, even Taiwan's own foreign minister is saying that China is on the cusp of a full scale invasion. But the good news is, if China invades Taiwan, there is a way to protect yourself.March 15, 2023 | marketwatch.comGlobal “Diffuse Large B Cell Lymphoma Drug Market” Research Forecast 2023-2028 | Latest Report with Growth AnalysisMarch 9, 2023 | marketwatch.comCaspase 3 Market: Analyzing Growth Opportunities and Industry Trends for 2023-2028March 9, 2023 | finance.yahoo.comAptose to Report Fourth Quarter and Full Year 2022 Financial Results and Hold Conference Call on Thursday, March 23, 2023March 8, 2023 | marketwatch.comCaspase 3 Market Size Global Research Report, 2023 - 2028January 30, 2023 | finance.yahoo.comAptose Initiates Dosing of Tuspetinib in APTIVATE Expansion Trial in Patients with Acute Myeloid LeukemiaMarch 21, 2023 | Behind the Markets (Ad)Buy THIS stock before Taiwan is attacked... If the United States goes to war with another nuclear armed superpower, this could have a devastating impact on your retirement portfolio. Now, even Taiwan's own foreign minister is saying that China is on the cusp of a full scale invasion. But the good news is, if China invades Taiwan, there is a way to protect yourself.January 18, 2023 | marketwatch.comCaspase 3 Market Detailed Analysis of Current Scenario with Growth Forecasts to 2028January 15, 2023 | marketwatch.comBruton's Tyrosine Kinase (BTK) Inhibitors Market Size 2023 with Presentation Outlook, Horizontal Viewpoint, global ViewJanuary 13, 2023 | marketwatch.comCaspase 3 Market Has Been Evolving in 2023 New Trends to ConsiderDecember 11, 2022 | finance.yahoo.comAptose Announces Updated Clinical Responses, Breadth of Activity, and Safety Across Four Dose Levels of Tuspetinib in Difficult-to-Treat Acute Myeloid Leukemia PopulationsDecember 11, 2022 | finance.yahoo.comAptose Announces Updated Clinical Responses, Breadth of Activity, and Safety Across Four Dose Levels of Tuspetinib in Difficult-to-Treat Acute Myeloid Leukemia PopulationsDecember 7, 2022 | finance.yahoo.comAptose to Hold Clinical Update and Data Review of AML Drug Tuspetinib on Sunday, December 11thDecember 7, 2022 | finance.yahoo.comAptose to Hold Clinical Update and Data Review of AML Drug Tuspetinib on Sunday, December 11thNovember 27, 2022 | marketwatch.comCaspase 3 Market is Expected to Record the Massive Growth, with Prominent Key Players Analysis and Forecast to 2028November 14, 2022 | finance.yahoo.comAptose Treats First Patient with Continuous Dosing of New “G3” Formulation of LuxeptinibNovember 7, 2022 | seekingalpha.comAptose Biosciences: Expansion Studies Could Rebuild Investor Interest In This Beaten-Down BiotechNovember 3, 2022 | finance.yahoo.comAptose Clinical Data to be Presented at the 2022 ASH Annual MeetingNovember 2, 2022 | markets.businessinsider.comH.C. Wainwright Reaffirms Their Buy Rating on Aptose Biosciences (APTO)November 1, 2022 | finance.yahoo.comAptose Reports Results for the Third Quarter 2022October 25, 2022 | marketwatch.comCaspase 3 Market Size in 2022-2028 | Top Companies & Analysts Certification up to 2028 with SWOT Analysis | New Report Spread Across 94 PagesOctober 18, 2022 | finance.yahoo.comAptose to Report Third Quarter 2022 Financial Results and Hold Conference Call on Tuesday, November 1, 2022October 17, 2022 | finance.yahoo.comAptose Biosciences Inc. (APTO)September 29, 2022 | finance.yahoo.comSanofi's (SNY) Dupixent Gets FDA Nod for Prurigo NodularisSeptember 20, 2022 | finance.yahoo.comSeagen's (SGEN) Tukysa Gets FDA Priority Review for New IndicationSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive APTO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Aptose Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address APTO Company Calendar Last Earnings11/11/2021Today3/20/2023Next Earnings (Confirmed)3/23/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:APTO CUSIPN/A CIK882361 Webwww.aptose.com Phone858-926-2730Fax905-234-2120Employees31Year FoundedN/APrice Target and Rating Average Stock Price Forecast$5.50 High Stock Price Forecast$6.00 Low Stock Price Forecast$5.00 Forecasted Upside/Downside+837.4%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($0.61) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-65,350,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-92.87% Return on Assets-81.08% Debt Debt-to-Equity RatioN/A Current Ratio5.53 Quick Ratio5.53 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.81 per share Price / Book0.72Miscellaneous Outstanding Shares92,370,000Free Float82,262,000Market Cap$54.19 million OptionableOptionable Beta1.50 Key ExecutivesDr. William G. Rice Ph.D. (Age 59)Chairman, Pres & CEO Mr. Gregory K. Chow CPA (Age 45)MBA, BA, Sr. VP, CFO & Principal Accounting Officer Mr. Ernest Kitt B.S.M.S, VP of Devel. & Technical OperationsDr. Stephen B. Howell (Age 73)Chief Medical Officer Mr. Peter MurrayDirector of Clinical Devel.Key CompetitorsAVROBIONASDAQ:AVROTaysha Gene TherapiesNASDAQ:TSHAElevation OncologyNASDAQ:ELEVEiger BioPharmaceuticalsNASDAQ:EIGRTradeUP AcquisitionNASDAQ:UPTDView All CompetitorsInsiders & InstitutionsDRW Securities LLCBought 8,892,437 shares on 2/15/2023Ownership: 9.627%Nantahala Capital Management LLCSold 835,955 shares on 2/15/2023Ownership: 6.553%Annandale Capital LLCBought 90,000 shares on 2/15/2023Ownership: 0.866%Morgan StanleySold 77,038 shares on 2/15/2023Ownership: 0.753%Millennium Management LLCBought 95,796 shares on 2/15/2023Ownership: 0.241%View All Insider TransactionsView All Institutional Transactions APTO Stock - Frequently Asked Questions Should I buy or sell Aptose Biosciences stock right now? 3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Aptose Biosciences in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" APTO shares. View APTO analyst ratings or view top-rated stocks. What is Aptose Biosciences' stock price forecast for 2023? 3 Wall Street research analysts have issued 1 year target prices for Aptose Biosciences' shares. Their APTO share price forecasts range from $5.00 to $6.00. On average, they anticipate the company's stock price to reach $5.50 in the next twelve months. This suggests a possible upside of 837.4% from the stock's current price. View analysts price targets for APTO or view top-rated stocks among Wall Street analysts. How have APTO shares performed in 2023? Aptose Biosciences' stock was trading at $0.58 at the start of the year. Since then, APTO shares have increased by 1.2% and is now trading at $0.5867. View the best growth stocks for 2023 here. When is Aptose Biosciences' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, March 23rd 2023. View our APTO earnings forecast. How can I listen to Aptose Biosciences' earnings call? Aptose Biosciences will be holding an earnings conference call on Thursday, March 23rd at 5:00 PM Eastern. Interested parties can register for or listen to the call using this link. How were Aptose Biosciences' earnings last quarter? Aptose Biosciences Inc. (NASDAQ:APTO) announced its quarterly earnings data on Thursday, November, 11th. The biotechnology company reported ($0.13) earnings per share for the quarter, beating the consensus estimate of ($0.17) by $0.04. During the same quarter in the previous year, the business earned ($0.15) EPS. What is William G. Rice, Ph.D.'s approval rating as Aptose Biosciences' CEO? 8 employees have rated Aptose Biosciences Chief Executive Officer William G. Rice, Ph.D. on Glassdoor.com. William G. Rice, Ph.D. has an approval rating of 34% among the company's employees. This puts William G. Rice, Ph.D. in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies. 52.0% of employees surveyed would recommend working at Aptose Biosciences to a friend. What other stocks do shareholders of Aptose Biosciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Aptose Biosciences investors own include Aurinia Pharmaceuticals (AUPH), Arch Therapeutics (ARTH), Aurora Cannabis (ACB), NVIDIA (NVDA), Advanced Micro Devices (AMD), Anavex Life Sciences (AVXL), CymaBay Therapeutics (CBAY), Cisco Systems (CSCO), Micron Technology (MU) and SCYNEXIS (SCYX). What is Aptose Biosciences' stock symbol? Aptose Biosciences trades on the NASDAQ under the ticker symbol "APTO." Who are Aptose Biosciences' major shareholders? Aptose Biosciences' stock is owned by many different retail and institutional investors. Top institutional investors include DRW Securities LLC (9.63%), Nantahala Capital Management LLC (6.55%), Sigma Planning Corp (1.16%), Annandale Capital LLC (0.87%), Morgan Stanley (0.75%) and Voss Capital LLC (0.60%). Insiders that own company stock include Denis R Burger, Donald R Jr Wilson, Erich Platzer, Gregory K Chow, Jotin Marango, Rafael Bejar, Warren Whitehead and William G Rice. View institutional ownership trends. How do I buy shares of Aptose Biosciences? Shares of APTO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Aptose Biosciences' stock price today? One share of APTO stock can currently be purchased for approximately $0.59. How much money does Aptose Biosciences make? Aptose Biosciences (NASDAQ:APTO) has a market capitalization of $54.19 million. The biotechnology company earns $-65,350,000.00 in net income (profit) each year or ($0.61) on an earnings per share basis. How can I contact Aptose Biosciences? Aptose Biosciences' mailing address is 251 CONSUMERS ROAD SUITE 1105, TORONTO A6, M2J 4R3. The official website for the company is www.aptose.com. The biotechnology company can be reached via phone at 858-926-2730, via email at ir@aptose.com, or via fax at 905-234-2120. This page (NASDAQ:APTO) was last updated on 3/21/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.